Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

INSM vs REGN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

REGN Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 9–1 Matrix Metrics)

REGN Overall Winner 6-Pillar Tally: INSM 0 – 6 REGN Matrix Metrics: INSM 1 – 9 REGN

As of Nov 19, 2026, Regeneron Pharmaceuticals Inc (REGN) is the stronger overall head-to-head candidate over Insmed, Inc. (INSM) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). INSM carries a Unified Composite Score of 35.9/100 (SELL) at $144.46 (N/M Forward P/E, -41.7% operating margin), whereas REGN carries 42.6/100 (HOLD) at $923.34 (14.9x Forward P/E, 30.4% operating margin).

  • Growth vs. Quality Trade-Off: REGN earns the overall head-to-head edge with a stronger Unified Composite Score (42.6/100 HOLD vs. INSM 35.9/100 SELL) and 0.32β · 55% Vol risk profile, whereas INSM leads top-line expansion (+268.4% YoY revenue growth, 1.09x PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About INSM vs REGN
INSM NASDAQ
Insmed, Inc.
Pharmaceutical Preparations
$144.46
+20.58% 1D
Market Cap $26.3B
TTM Revenue $1.52B
Forward P/E N/M
Beta / 30D Vol 0.40β · 90% Vol
Unified Composite Score
35.9 / 100 SELL
Tech 5.0 Fund 35.0 Flow 66.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 77
RSI-14: 77.2 · SMA20: $112.72 · SMA50: $110.86
REGN NASDAQ Head-to-Head Winner
Regeneron Pharmaceuticals Inc
Pharmaceutical Preparations
$923.34
-2.35% 1D
Market Cap $97.8B
TTM Revenue $16.9B
Forward P/E 14.9x
Beta / 30D Vol 0.32β · 55% Vol
Unified Composite Score
42.6 / 100 HOLD
Tech 19.0 Fund 45.0 Flow 68.0 Mom 56.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (4.5% over 20 days), RSI 58
RSI-14: 57.9 · SMA20: $907.12 · SMA50: $826.97

6-Pillar Scorecard Institutional Category Breakdown (INSM 0 – 6 REGN)

Columns: Metric · INSM · REGN
1. Valuation Multiples REGN
Forward P/E N/M 14.9x
Trailing P/E 107.5x 20.9x
PEG Ratio 1.09x 1.15x
EV / Revenue 17.4x 5.7x
2. Growth & Scale REGN
Revenue Growth (YoY) +268.4% +36.3%
Earnings Growth (YoY) +0.0% +35.5%
TTM Revenue (USD) $1.52B $16.9B
Market Cap $26.3B $97.8B
3. Profitability & Quality REGN
Gross Margin 84.4% 46.7%
Operating Margin -41.7% 30.4%
Net Profit Margin -39.9% 28.5%
Return on Equity (ROE) -72.5% 14.9%
4. Balance Sheet & Cash Flow REGN
Cash Generation (TTM) -$628M $3.63B
Cash Flow Margin -41.3% 21.5%
Net Cash / Leverage $188M Net Debt (0.81x D/E) $952M Net Cash
Dividend Yield None (0.00%) 0.39%
5. Options & Positioning REGN
Options Structure Phase CONSOLIDATION CONSOLIDATION
Current IV / %ile 52.5% (38th %ile) 35.5% (6th %ile)
Put/Call OI Skew 0.16x (Call-Skewed) 0.47x (Call-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Neutral ACCUMULATION · Markup
6. R&D & Supply-Chain Moat REGN
OpEx & R&D Intensity N/A 16.3% of Rev ($2.75B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: INSM (1) vs REGN (9)
Institutional Metric INSM REGN Criterion Row Edge
Market Capitalization
Scale
$26.3B $97.8B Larger Scale REGN
Trailing P/E Ratio
Valuation
107.5x 20.9x Lower Multiple REGN
Forward P/E Ratio
Valuation
N/M 14.9x Lower Multiple REGN
Revenue Growth (YoY)
Growth
+268.4% +36.3% Higher Growth INSM
Operating Margin (TTM)
Profitability
-41.7% 30.4% Higher Margin REGN
Net Profit Margin
Profitability
-39.9% 28.5% Higher Margin REGN
Return on Equity (ROE)
Capital Efficiency
-72.5% 14.9% Higher ROE REGN
52-Week Range Position
Momentum
44% ($90–$213) 83% ($592–$992) Stronger Trend REGN
Beta / 30D Volatility
Risk Regime
0.40β · 90% Vol 0.32β · 55% Vol Lower Realized Risk REGN
Unified Institutional Score
Composite Signal
35.9 / 100 (SELL) 42.6 / 100 (HOLD) Higher Composite REGN
Trailing 12M Revenue (USD)
Operating Scale
$1.52B $16.9B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
84.4% 46.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.09x PEG · 17.4x EV/Rev 1.15x PEG · 5.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$628M ($188M Net Debt (0.81x D/E)) $3.63B ($952M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon INSM +39.01 pp
INSM: +53.62% · REGN: +14.61%
3M Horizon INSM +4.15 pp
INSM: +14.86% · REGN: +10.71%
6M Horizon REGN +11.8 pp
INSM: +31.89% · REGN: +43.69%
1Y Horizon REGN +55.65 pp
INSM: -28.35% · REGN: +27.3%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period INSM Revenue REGN Revenue INSM Op. Margin REGN Op. Margin Margin Leader
FY2018 $10M $5.15B -3124.9% 49.3% REGN
FY2019 $140M $6.56B -172.4% 33.7% REGN
FY2020 $160M $8.50B -161.3% 42.1% REGN
FY2021 $190M $16.1B -199.0% 55.7% REGN
FY2022 $250M $12.2B -186.4% 38.9% REGN
FY2023 $310M $13.1B -232.5% 30.9% REGN
FY2024 $360M $14.2B -241.5% 28.1% REGN
FY2025 $610M $14.3B -205.6% 24.9% REGN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
INSM CONSOLIDATION
72d in phase · OBV ACCUMULATION
Current IV 52.5%
IV Percentile 38th %ile
Put/Call OI Skew 0.16x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact INSM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
REGN CONSOLIDATION
55d in phase · OBV ACCUMULATION
Current IV 35.5%
IV Percentile 6th %ile
Put/Call OI Skew 0.47x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact REGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $122.88 · IV 50.1%

INSM vs. REGN: Simulated 5-Day Option Payoffs & Capital Efficiency

Compare 100 shares of INSM ($12,288) vs. REGN ($95,240) against risk-defined 5-day vertical and put-wall option structures.

INSM Spot $122.88 · IV 50.1%
INSM Options Simulator →
5-DAY BULLISH SWING Liq B

Dec 18 $125 / $135 Bull Call Spread

Buy 1x $125C · Sell 1x $135C · 32d

Net Entry $360 Debit
T+5d @ +5% Move +$119 (+33%)
Max Risk / Buffer $360 Capped
5d Edge & Liquidity 0.8x R:R · Liq B
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq C

Jan 15 '27 $110 / $100 Bull Put Spread

Sell 1x $110P · Buy 1x $100P · 60d

Net Entry $215 Credit
Max Credit / Yield +$215 (+27.4% RoM)
Max Risk / Buffer -12.2% Cushion ($785 Mgn)
5d Edge & Liquidity 75% PoP · Liq C
Simulate 5-Day Payoff →
REGN Spot $952.40 · IV 33.5%
REGN Options Simulator →
5-DAY BULLISH SWING Liq C

Dec 18 $950 / $1,000 Bull Call Spread

Buy 1x $950C · Sell 1x $1,000C · 31d

Net Entry $2,387 Debit
T+5d @ +5% Move +$891 (+37%)
Max Risk / Buffer $2,387 Capped
5d Edge & Liquidity 0.8x R:R · Liq C
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq C

Jan 15 '27 $880 / $820 Bull Put Spread

Sell 1x $880P · Buy 1x $820P · 59d

Net Entry $1,367 Credit
Max Credit / Yield +$1,367 (+29.5% RoM)
Max Risk / Buffer -9.0% Cushion ($4,633 Mgn)
5d Edge & Liquidity 75% PoP · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
INSM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $26.3B market capitalization and -41.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
REGN Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $97.8B market capitalization and 30.4% operating margin.
OpEx & R&D Reinvestment 16.3% of Rev ($2.75B)
90D Engineering Disclosures 0 Published

Investor FAQ INSM vs REGN Key Questions & Quantitative Answers

As of Nov 19, 2026, Regeneron Pharmaceuticals Inc (REGN) is the stronger overall head-to-head candidate over Insmed, Inc. (INSM) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). INSM carries a Unified Composite Score of 35.9/100 (SELL) at $144.46 (N/M Forward P/E, -41.7% operating margin), whereas REGN carries 42.6/100 (HOLD) at $923.34 (14.9x Forward P/E, 30.4% operating margin). Growth vs. Quality Trade-Off: REGN earns the overall head-to-head edge with a stronger Unified Composite Score (42.6/100 HOLD vs. INSM 35.9/100 SELL) and 0.32β · 55% Vol risk profile, whereas INSM leads top-line expansion (+268.4% YoY revenue growth, 1.09x PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates.

REGN leads the Growth & Scale pillar: INSM posts +268.4% YoY revenue growth and +0.0% YoY earnings growth on $1.52B TTM revenue (84.4% gross margin, -41.7% operating margin), compared with REGN at +36.3% YoY revenue growth and +35.5% YoY earnings growth on $16.9B TTM revenue (46.7% gross margin, 30.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), INSM cumulative revenue shifted +6000.0% while REGN shifted +178.4%. In operating R&D and SG&A reinvestment, INSM deploys N/A (0 90-day corporate R&D disclosures) versus 16.3% of Rev ($2.75B) (0 disclosures) for REGN.

REGN screens cheaper on headline valuation multiples. INSM trades at N/M Forward P/E, 107.5x Trailing P/E, 1.09x PEG, and 17.4x EV/Revenue (-41.3% FCF margin), whereas REGN trades at 14.9x Forward P/E, 20.9x Trailing P/E, 1.15x PEG, and 5.7x EV/Revenue (21.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against INSM (-72.5% ROE) versus REGN (14.9% ROE) capital efficiency.

In options market volatility and institutional positioning, INSM carries 52.5% implied volatility (38th %ile, Balanced (25th–60th %ile)), a 0.16x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.40β · 90% Vol realized risk). By comparison, REGN carries 35.5% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.47x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.32β · 55% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.